Quality of Life and Tamoxifen in a Breast Cancer Prevention Trial
Author:
- 1 December 2001
- journal article
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 949 (1) , 143-150
Abstract
Abstract: This report contains a brief summary of the health‐related quality of life findings for 11,064 women taking part in the National Surgical Adjuvant Breast and Bowel Project's P‐1 trial. Women taking part in this trial of tamoxifen versus placebo for breast cancer prevention were ≥35 years old and predominantly white, well educated, and middle class, with a strong professional and technical orientation. Key findings included a lack of difference between the tamoxifen and placebo arms with regard to depression, overall physical or mental quality of life, and weight gain. The tamoxifen arm did show consistent increases in vasomotor (hot flashes) and gynecological (vaginal discharge) symptoms, as well as difficulties in certain domains of sexual functioning. It is concluded that an informed discussion with a woman considering tamoxifen therapy should include these points in the risk‐benefit discussion.Keywords
This publication has 14 references indexed in Scilit:
- Health-Related Quality of Life and Tamoxifen in Breast Cancer Prevention: A Report From the National Surgical Adjuvant Breast and Bowel Project P-1 StudyJournal of Clinical Oncology, 1999
- Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 StudyJNCI: Journal of the National Cancer Institute, 1998
- Compliance with quality of life data collection in the National Surgical Adjuvant Breast and Bowel Project (NSABP) Breast Cancer Prevention TrialStatistics in Medicine, 1998
- Five Versus More Than Five Years of Tamoxifen Therapy for Breast Cancer Patients With Negative Lymph Nodes and Estrogen Receptor-Positive TumorsJNCI: Journal of the National Cancer Institute, 1996
- Base-Line Quality-of-Life Assessment in the National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention TrialJNCI: Journal of the National Cancer Institute, 1995
- Mood Disorder in Women with Early Breast Cancer Taking Tamoxifen, an Estradiol Receptor AntagonistAnnals of the New York Academy of Sciences, 1995
- Clinical recognition and management of depression in node negative breast cancer patients treated with tamoxifenBreast Cancer Research and Treatment, 1993
- A Randomized Clinical Trial Evaluating Tamoxifen in the Treatment of Patients with Node-Negative Breast Cancer Who Have Estrogen-Receptor–Positive TumorsNew England Journal of Medicine, 1989
- The Center for Epidemiologic Studies Depression Scale: its use in a community sampleAmerican Journal of Psychiatry, 1983
- The CES-D ScaleApplied Psychological Measurement, 1977